Pfenex And Alvogen May Face Delay In Teriparatide Equivalence Rating

 
• By Aidan Fry

Pfenex remains hopeful of receiving US approval for its teriparatide hybrid rival to Eli Lilly’s Forteo in October this year. But commercial partner Alvogen may have to wait for a therapeutic equivalence rating to the osteoporosis original.

Delayed
Obtaining a therapeutic equivalence rating for Pfenex' hybrid teriparatide device in the US could be delayed by a lack of FDA feedback on a study protocol • Source: Shutterstock

More from Value Added Medicines

More from Products